Back to Search
MONICA MITA, MD
MD
Medical Oncology Physician
NPI: 1760450043IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
M3029(TX)
CMS Specialties
PrimaryHEMATOLOGY/ONCOLOGY
Education
OTHER
Class of 1992
Research & Publications (20)
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.
PMID 19633048·Ann Oncol·2010
3-trial
Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
PMID 19034451·Cancer Chemother Pharmacol·2009
3-trial
Deforolimus (AP23573) a novel mTOR inhibitor in clinical development.
PMID 19012509·Expert Opin Investig Drugs·2008
6-review
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
PMID 18202410·J Clin Oncol·2008
3-trial
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
PMID 16736151·Cancer Chemother Pharmacol·2007
3-trial
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.
PMID 16322117·Ann Oncol·2006
3-trial
Mammalian target of rapamycin: a new molecular target for breast cancer.
PMID 12864941·Clin Breast Cancer·2003
6-review
Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.
PMID 19583815·J Cell Mol Med·2010
7-preclinical
Expression and distribution of gonad-stimulating substance in various organs of the starfish Asterina pectinifera.
PMID 19456390·Ann N Y Acad Sci·2009
7-preclinical
A relaxin-like peptide purified from radial nerves induces oocyte maturation and ovulation in the starfish, Asterina pectinifera.
PMID 19470645·Proc Natl Acad Sci U S A·2009
7-preclinical
A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
PMID 19509177·Clin Cancer Res·2009
3-trial
Determination of D-serine and D-alanine in the tissues and physiological fluids of mice with various D-amino-acid oxidase activities using two-dimensional high-performance liquid chromatography with fluorescence detection.
PMID 19586804·J Chromatogr B Analyt Technol Biomed Life Sci·2009
7-preclinical
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.
PMID 19451436·J Clin Oncol·2009
3-trial
Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.
PMID 19417019·Clin Cancer Res·2009
3-trial
The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents.
PMID 19381454·Target Oncol·2009
6-review
Targeting the mTOR pathway using deforolimus in cancer therapy.
PMID 19374536·Future Oncol·2009
6-review
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
PMID 18795291·Cancer Chemother Pharmacol·2009
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 7979 WURZBACH RD
SAN ANTONIO, TX 78229 - Phone
- (210) 450-1000
Quick Facts
- NPI
- 1760450043
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 34
- Publications
- 20
Are you this provider?
Claim Your Profile